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PDX1 is a transcription factor of
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development and b cell function. Here,
McKenna et al. show how context-
dependent recruitment of coregulatory
complexes impacts PDX1 activity, thus
linking ATP-dependent chromatin
remodeling to control of islet b cell
function under normal and disease
conditions.
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Pdx1 is a transcription factor of fundamental im-
portance to pancreas formation and adult islet b
cell function. However, little is known about the pos-
itive- and negative-acting coregulators recruited to
mediate transcriptional control. Here, we isolated
numerous Pdx1-interacting factors possessing a
wide range of cellular functions linked with this pro-
tein, including, but not limited to, coregulators asso-
ciated with transcriptional activation and repres-
sion, DNA damage response, and DNA replication.
Because chromatin remodeling activities are essen-
tial to developmental lineage decisions and adult
cell function, our analysis focused on investigating
the influence of the Swi/Snf chromatin remodeler
on Pdx1 action. The two mutually exclusive and
indispensable Swi/Snf core ATPase subunits, Brg1
and Brm, distinctly affected target gene ex-
pression in b cells. Furthermore, physiological and
pathophysiological conditions dynamically regu-
lated Pdx1 binding to these Swi/Snf complexes
in vivo. We discuss how context-dependent recruit-
ment of coregulatory complexes by Pdx1 could
impact pancreas cell development and adult islet b
cell activity.INTRODUCTION
The Pdx1 protein has profound transcriptional regulatory proper-
ties and is an essential driver of normal pancreas development
and mature b cell function. For example, embryonic formation
of ductal, acinar, and islet cells that compose the pancreas are
derived from a common Pdx1-expressing progenitor pool (Jons-
son et al., 1994; Offield et al., 1996), with pancreas agenesis
manifested in mice and humans unable to produce the functional
protein (Jonsson et al., 1994; Offield et al., 1996; Stoffers et al.,
1997). Developing mouse b (Gannon et al., 2008) and/or acinar
cell (Hale et al., 2005) formation is also severely blunted upon2032 Cell Reports 10, 2032–2042, March 31, 2015 ª2015 The AuthorPdx1 removal from the progenitors of these cell populations.
Moreover, forced and persistent Pdx1 expression in embryonic
Neurogenin 3 (Ngn3)+ pan-endocrine cell progenitors causes
islet glucagon hormone+ a cells to become insulin+ b cells post-
natally (Yang et al., 2011). Conversely, specific deletion of Pdx1
from adult islet b cells, which are the principal adult pancreatic
cell type producing this protein, results in their rapid acquisition
of an a-like cell identity (Gao et al., 2014).
Like all transcription factors, Pdx1 binds to specific cis-acting
sequences within target gene control regions, often referred to
as enhancer regions (Pasquali et al., 2014). Transcriptional mod-
ulation is then imposed through dynamic changes in chromatin
structure that causes the underlying DNA to become more or
less accessible to RNA polymerase II. However, even powerful
transcription factors like Pdx1 lack inherent chromatin-modi-
fying properties and alone cannot modulate gene transcription
effectively. Instead, cell-signaling events drive context-depen-
dent protein-protein interactions between these DNA-binding
factors and coregulators, which possess transcriptional modi-
fying functions. For example, acute exposure of b cell lines to
glucose, the most important physiological effector of cell func-
tion in vivo, causes a rapid activator/repressor switch in Pdx1 ac-
tivity on Insulin gene transcription. This involves the differential
recruitment of histone acetyltransferases (HAT) coactivator at
high, stimulating glucose concentrations, and histone deacety-
lase (HDAC) corepressors at low, inhibitory glucose levels (Mos-
ley and Ozcan, 2004; Mosley et al., 2004).
Coregulators that alter chromatin structure can do so by both
enzymatic and non-enzymatic means. Non-enzymatic coregula-
tors such as Mediator harbor protein-protein and protein-DNA/
RNA interaction surfaces that influence transcription by altering
epigenetic patterns, chromatin compaction, as well as the re-
cruitment of distinct cofactors and RNA Polymerase II (Poss
et al., 2013). The coregulators that function enzymatically can
be divided into two main mechanistically distinct classes. First
are those that alter chromatin through covalent modifications
to DNA (e.g., methylation) and DNA-binding proteins (e.g., his-
tones, transcription factors, and coregulators by acetylation,
methylation, phosphorylation, ubiquitination, sumoylation, and/
or glycosylation) (Bhaumik et al., 2007; Chen and Li, 2004; Flotho
and Melchior, 2013; Wells et al., 2003). Second are those that
use the energy of ATP hydrolysis to destabilize nucleosomess
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Figure 1. ReCLIP Enriches for Pdx1-Interacting Proteins
(A) Diagram of ReCLIP showing the lysine-reactive cross-linking reagent, DSP, that is first incubated with b cells fromwhich nuclear extract is generated for Pdx1
antibody or IgG immunoprecipitation. The control and a-Pdx1-bound complexes were washed with RIPA buffer and then RIPA + DTT to elute bound cross-linked
proteins.
(B) Nearly all of Pdx1 was removed from the coIP supernatants with Pdx1 antibody.
(C and D) The eluted proteins were (C) SDS-PAGE separated and submitted for MS analysis or (D) immunoblotted with MafA or Set7/9 antibodies (Tables 1 and
S1) (nR 3).and alter the accessibility of DNA to the transcriptional machin-
ery (Sudarsanam and Winston, 2000). While there are over
250 transcriptional coregulators in mammalian cells, relatively
few have been ascribed to Pdx1 specifically (Pcif1, p300,
HDAC1/2, Set7/9, and Bridge1 [Francis et al., 2005; Liu et al.,
2004; Mosley and Ozcan, 2004; Qiu et al., 2002; Stanojevic
et al., 2005]) or other islet-enriched transcription factors like
Nkx2.2 (Grg3, HDAC1, and DNMT3a [Papizan et al., 2011]),
Isl1 (Ldb1/2 [Hunter et al., 2013]), HNF1b (PCAF/CBP [Barbacci
et al., 2004]), and NeuroD1 (Bridge1 and p300/CBP [Qiu et al.,
1998; Thomas et al., 1999]). Significantly, essentially all of these
transcription factor associations were made in studies using a
small subset of candidate coregulators.
Here we have used an unbiased chemical cross-linking, anti-
body precipitation, and mass spectrometry (MS) strategy to
identify endogenous Pdx1-binding proteins in b cells. Although
many new and interesting coregulatory factors were found using
this in-cell cross-linking approach, we chose to specifically
focus on investigating whether Swi/Snf chromatin remodeling
complex recruitment was linked to the positive- and/or nega-
tive-acting control properties of Pdx1. Our results strongly sug-
gest that Pdx1 interacts with functionally distinct Swi/Snf com-
plexes in a highly dynamic manner in islet b cells. Hence, Swi/
Snf complexes containing the core Brg1 ATPase subunit were
demonstrated to be involved in Pdx1-mediated activation, while
the Brm ATPase subunit containing complexes imposed tran-
scriptional repression. Evidence is also presented indicating
that physiological and pathophysiological conditions influence
Pdx1 binding to these distinct complexes in b cells in vivo, andCellwe propose that the antagonistic actions of Brg1-Swi/Snf and
Brm-Swi/Snf have significant implications to glucose homeosta-
sis. Our findings have identified many different possible coregu-
lators of Pdx1 and shed light on how their recruitment and
consequent transcription factor function is impacted normally
and in the context of dysfunctional type 2 diabetes mellitus
(T2DM) b cells.RESULTS
Pdx1 Interacts with Many Functionally Distinct
Coregulatory Proteins in b Cells
An unbiased strategy of reversible cross-linking, co-immunopre-
cipitation (ReCLIP [Smith et al., 2011]) and MSwas used to iden-
tify Pdx1-interacting proteins in bTC3 cells, a murine b cell line
(Figure 1A). Employment of the cell-permeable, lysine-reactive,
thiol-cleavable dithiobis(succinimidyl propionate) (DSP) cross-
linking reagent allowed for stringent detergent-based washes,
which led to a very clear difference in the proteins obtained
from the Pdx1 antibody and control precipitates (Figures 1B
and 1C). As anticipated, established Pdx1-interacting factors
such as the MafA transcription factor (Zhao et al., 2005) and
the Set7/9 coregulator (Francis et al., 2005) were found by immu-
noblot analysis after Pdx1 precipitation (Figure 1D). Additionally,
we identified a number of novel candidate Pdx1-binding factors
by MS (Table 1; Table S1). Many of the candidates are likely
linked with Pdx1 transcriptional regulation, while others may be
associated with context-dependent recruitment in, for example,Reports 10, 2032–2042, March 31, 2015 ª2015 The Authors 2033
Table 1. Pdx1-Bound Chromatin Remodeling Complexes
Identified by ReCLIP/MS
Coregulator Protein Coverage (%)
Peptides
IgG Control Pdx1 IP
NuRD complex Rbbp4 9 1 10
Hdac1/2 4 0 5
Mi-2b 3 0 7
Swi/Snf complex Baf47 11 0 1
Baf155 3 0 3
Baf57 9 0 2
Baf170 3 0 3
Brg1 2 0 5
Tif1b Tif1b 14 0 6
The coregulator complex is shown as well as the MS results illustrating
percentage protein subunit coverage and the number of peptides found
by IgG or Pdx1 antibody precipitation. These results are representative of
data averaged from at least three independently performed IgG and Pdx1
antibody treatments.DNA repair, proliferation, and apoptosis (Babu et al., 2007; Leb-
run et al., 2005).
Several of the transcriptional coregulators were of particular
interest because of their ability to potentially activate and/or
repress Pdx1 trans-regulation (e.g., Tif1b, Swi/Snf, and NuRD)
(Flowers et al., 2009; Iyengar et al., 2011; Miccio et al., 2010).
The binding of Tif1b, Swi/Snf, and NuRD complex proteins to
Pdx1 was independently confirmed in co-immunoprecipitation
(coIP) experiments performed with both mouse and human b
cell lines (Figure 2A). The authenticity of the interactions was
further verified by the ability to precipitate Pdx1with specific cor-
egulator antibodies (Figure 2B). In addition, the roughly 42 kDa
Pdx1 protein was found to migrate as a high molecular weight
complex after sucrose gradient sedimentation of bTC3 nuclear
extracts (Figure 2C), and to bind to Swi/Snf complex subunits
by coIP analysis (Figure 2E). Moreover, Pdx1-Swi/Snf was
shown to retain specific cis-control-element-binding properties
in electrophoretic mobility shift assays (EMSAs) (Figure 2D).
Notably, few of the published Pdx1 coregulators and none of
the interacting islet-enriched transcription factors were detected
byMS (Table 1; Table S1).We presume that these represent rela-
tively rare complexes observed by more sensitive analytical
methods (e.g., immune-based analysis). Significantly, these ex-
periments identified a number of new, interesting interacting
candidate proteins involved in Pdx1 action.
Pdx1 Interacts in the Developing and Adult Pancreas
with Brg1 and Brm, the Catalytic ATPase Subunits of the
Swi/Snf Complex
The contribution of Swi/Snf to Pdx1 activity was further investi-
gated because of the prominent actions of this coregulator in
developing neuron, cardiomyocyte, and lymphocyte cell prolifer-
ation and lineage decisions (Chi et al., 2003; Lessard et al., 2007;
Lickert et al., 2004). Immunofluorescence analysis revealed that
the ATPase subunits of Swi/Snf, Brg1 and Brm, were broadly ex-
pressed in the embryonic and adult pancreas, with no observ-
able difference in protein level between cell types within each2034 Cell Reports 10, 2032–2042, March 31, 2015 ª2015 The Authordevelopmental stage (Figures S2A and S2B). Because of the
unique and dynamic expression pattern of Pdx1 in the pancreas,
this transcription factor would be coexpressed with Brm- and
Brg1-Swi/Snf within multipotent pancreatic progenitor cells dur-
ing early embryogenesis (i.e., embryonic day E12.5 [Offield et al.,
1996]), and then principally in the insulin+ cells of developing
(E15.5, E18.5) and adult islet b cells that express relatively high
levels of Pdx1 (termed Pdx1High [Boyer et al., 2006]), and not
acinar, ductal, or other islet cell types (i.e., a, ε, d, and PP) (Guz
et al., 1995; Ohlsson et al., 1993).
The proximity ligation assay (PLA) was next used to evaluate
Pdx1 binding to Brg1 and Brm in the forming and adult pancreas.
In this assay, a fluorescent signal is generated if Pdx1 is within
30–40 nm of these Swi/Snf proteins, a physical distance only
producing a signal for neighboring proteins. However, the sig-
nals are not a reflection of the absolute quantity of Pdx1:Brg1-
Swi/Snf or Pdx1:Brm1-Swi/Snf complexes in a cell due to anti-
body quality and/or other vagaries of the assay. Significantly,
Pdx1:Brg1 and Pdx1:Brm signals were detected in nearly all
Pdx1+ pancreatic progenitors of the E12.5 pancreatic epithelium
(Figures S3A and S3B). In contrast, no Brg1 or Brm PLA binding
was observed using antibodies specific for Sox9 (Seymour et al.,
2007) or Ptf1a (Krapp et al., 1998), other key transcription factors
enriched in this multipotent progenitor population (data not
shown). Notably, Pdx1:Brg1 and Pdx1:Brm signals became
confined to insulin+ cells later in development and in islets (Fig-
ures S3A and S3B). These experimental results demonstrate
that Pdx1 interacts with the core catalytic subunits of Swi/Snf
in the developing and adult mouse pancreas, which we conclude
represents greater Swi/Snf complex recruitment. Furthermore,
the progressive restriction of binding to insulin+ cells supports
the specific nature of these interactions, and implies functional
relevance upon consideration of the many established roles of
Swi/Snf in other cell types (Chi et al., 2003; Lessard et al.,
2007; Lickert et al., 2004).
Blood Glucose Concentration Dynamically Regulates
Pdx1:Brg1 Levels in Mouse Islet b Cells
We next asked whether Pdx1:Swi/Snf complex formation was
regulated in a glucose-dependent manner in vivo by comparing
PLA signal numbers in pancreata prepared from fastedmicewith
low blood glucose levels to those fasted then given an intraper-
itoneal injection of a high-glucose solution (Figure 3A). Strikingly,
the number of Pdx1:Brg1 complexes was significantly increased
compared to fasted and fed (ad libitum) controls 30 min after
glucose treatment, as shown quantitatively by the specific in-
crease per b cell nucleus after high-glucose treatment (Figures
3B and 3C). Additionally, fed (ad libitum) and fasted mouse islets
had roughly 3- and 5-fold more b cells displaying zero detectible
PLA signals than glucose-injected animals (Figure 3D). These
data illustrate a strong, positive relationship between high-
glucose conditions that stimulate Pdx1 b cell activity and
Pdx1:Brg1 binding (Figure 3C). Supporting the specific nature
of these interactions, no PLA signals were detected under these
conditions between Pdx1 and Isl1 transcription factor coregula-
tor, Ldb1 (Hunter et al., 2013; Figure S4). Interestingly, although
the Pdx1:Brm signals changed some under these conditions,
relatively few of the data points were significantly differents
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Figure 2. Proteins in NuRD, Tif1b, and Swi/
Snf Immunoprecipitatedwith Pdx1 inMouse
bTC3 and Human EndoC-bH1 Cells
(A) Proteins of the Swi/Snf (Brg1 and Brm) and
NuRD (Rbbp4 and Mi2) complexes and Tif1b were
enriched in Pdx1 antibody ReCLIP precipitations
of bTC3 (left) and EndoC-bH1 (right) extracts.
(B) Reverse coIPs illustrate Pdx1 enrichment in
bTC3 nuclear extracts immunoprecipitated with
Tif1b, Swi/Snf, and NuRD coregulator subunit an-
tibodies (Figure S1).
(C–E) Sucrose gradient sedimentation demon-
strates that the Pdx1 (C) migrating in the highest
molecular weight fraction retains the ability to (D)
bind Pdx1-regulated control element DNA and (E)
coprecipitate with SWI/SNF complex subunits (n
R 3 for each coIP).among low, ad libitum, and high-glucose conditions (Figure 3E).
In addition, the number of b cells harboring zero detectible
Pdx1:Brm PLA signals was not altered (Figure 3F). These results
indicate that blood glucose signaling dynamically regulates Pdx1
and Brg1-Swi/Snf association.
Brg1 and Brm Play Opposing Roles in the Regulation of
b-Cell-Specific Genes
Brg1 or Brm are incorporated into Swi/Snf complexes in a mutu-
ally exclusive manner (Wang et al., 1996). These two ATPases
share 74% amino acid sequence identity and have similar
in vitro biochemical activity (Khavari et al., 1993; Phelan et al.,
1999). Brg1 and Brm have the capacity to compensate for
each other in heterozygous ATPase subunit mutant mice during
development, although their combined gene dosage is critical to
function (Bultman et al., 2000; Smith-Roe and Bultman, 2013;
Willis et al., 2012). Null mutants of nearly ubiquitously expressed
Brg1 and Brm manifest different phenotypes in vivo. Thus,
Brg1/ mice die at the preimplantation stage of development
(Bultman et al., 2000), while Brm/ mice survive to adulthood
with only a roughly 15% increase in body mass, which is
attributed to greater bone density (Reyes et al., 1998). Intrigu-
ingly, these ATPases have distinct and antagonistic roles in hu-
man osteoblast formation, with depletion of BRG1 hindering
differentiation and BRM accelerating it (Flowers et al., 2009).Cell Reports 10, 2032–2042BRM-SWI/SNF represses transcription
of differentiation genes such as osteocal-
cin in osteoblast progenitors, at least in
part through recruitment of the HDAC1
corepressor. In contrast, BRM and
HDAC1 dissociate from the osteocalcin
promoter during differentiation, allowing
activating BRG1-specific complexes to
initiate transcription. These experiments
reveal how recruitment of BRG1- or
BRM-containing SWI/SNF complexes
can produce different transcriptional
outcomes.
Pdx1 both activates and represses
gene transcription in islet b cells (Gao
et al., 2014). Quantitative chromatin immunoprecipitation
(ChIP)-qPCR assays were performed in mouse Min6 b cells
with Brg1- and Brm-specific antibodies to examine their pattern
of recruitment to genes that Pdx1 either directly stimulates (i.e.,
b cell-enriched Insulin, MafA, and Pdx1) or inhibits (i.e., islet a
cell-enriched MafB and Glucagon [Artner et al., 2006; Gao
et al., 2014]). Brg1 was recruited to genes stimulated by Pdx1
in b cells (Figure 4). However, antibody reagent limitations
precluded our ability to detect Brm control region binding, as
illustrated by our inability to even detect control, bona fide
Brm-binding sites in this assay (Figure S5A).
Depletion of Pdx1 from either islet b cells in vivo or b cell lines
causes a rapid loss in cell identity marker expression (e.g., MafA,
Glut2, and insulin), and activation of islet a cell-specific genes
(e.g., MafB and glucagon) (Gao et al., 2014). The induction of islet
a cell-enriched MafB transcription factor expression was a
driving force in glucagon transcription. These studies clearly
illustrate the critical role of Pdx1 in maintaining b cell identity.
We therefore sought to investigate how depletion of Brg1 or
Brm in rat INS-1 b cells influenced Pdx1-mediated transcrip-
tional control. Brg1 and Brm small interfering RNA (siRNA) tar-
geting decreased protein levels by roughly 65% (Figure 5A)
and 55% (Figure 5C), respectively. As expected from the ChIP
results, Brg1 knockdown resulted in a significant reduction in In-
sulin,MafA, and Glut2 transcript levels (Figure 5B). Interestingly,, March 31, 2015 ª2015 The Authors 2035
Figure 3. Pdx1:Brg1 Complex Formation Is
Acutely Regulated by Blood Glucose Con-
centration In Vivo
(A) Diagram showing mouse blood glucose con-
centration and time of ad libitum (AL), low-glucose
(16-hr fast [LG]), and high-glucose (16-hr fast +
glucose injection [HG]) conditions; arrows repre-
sent time of sacrifice and pancreas fixation.
(B) Pdx1:Brg1 PLA/immunofluorescence analysis
of islet b cell nuclei reveals that Pdx1:Brg1 signals
become more abundant with increasing blood
glucose concentration. Representative images are
shown with PLA signals appearing as white spots;
lower magnification insets are provided to orient
each image. Scale bars, 5 mM.
(C–F) (C) The distribution of insulin+ PLA signals
under high-glucose conditions were significantly
greater than in low or ad libitum b cells, although
the (E) Pdx1:Brm population was essentially un-
changed. Islets from high-glucose conditions
possessed significantly fewer b cells displaying
zero detectible (D) Pdx1:Brg1 signals than low
or ad libitum conditions. This pattern was not
observed for (F) Pdx1:Brm between glucose con-
ditions (nR 3, *p < 0.05).
Error bars represent SD.Brm depletion led to increased Insulin, Glut2, Ucn3, and MafB
transcripts (Figure 5D). Our data strongly indicate that Brg1-
Swi/Snf serves as a coactivator of Pdx1-mediated gene expres-
sion in islet b cells, whereas Brm-Swi/Snf acts in a corepressive
manner.2036 Cell Reports 10, 2032–2042, March 31, 2015 ª2015 The AuthorsPDX1 Recruitment of BRG1-SWI/
SNF Is Compromised in Human
T2DM Islet b Cells
Reduced levels of a small subset of islet-
enriched transcription factors contribute
to T2DM b cell dysfunction, with PDX1
among the specifically affected factors
(Guo et al., 2013). We therefore sought
to investigate whether alterations in
PDX1:SWI/SNF complex formation could
be contributing to diminished b cell activ-
ity. PDX1 binding to BRG1 (Figure 6A) and
BRM (Figure 6D) was readily detected in
normal human islet b cell nuclei. How-
ever, only insulin+ PDX1:BRG1 (Figure 6B)
signal numbers were significantly dimin-
ished in age-, sex-, and BMI-matched
T2DM samples, and not PDX1:BRM (Fig-
ure 6E). The change in PDX1:BRG1 levels
paralleled that of PDX1 in T2DM islet b
cells (Guo et al., 2013), whereas there
was no apparent change in BRG1 or
BRM levels compared to normal tissue
(Figures S2C and S2D). In addition, there
was a roughly 2-fold increase in the num-
ber of b cells with zero PLA signals in the
PDX1:BRG1 T2DM samples (Figure 6C),
even though PDX1:BRM levels were unaffected (Figure 6F).
This suggests that the quantitative change in the amount of
PDX1 protein affects BRG1-SWI/SNF coactivator binding in
T2DM b cells, and not the BRM-SWI/SNF corepressor. Collec-
tively, these results strongly indicate that the association of
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Figure 4. Brg1 Binds to Pdx1-Activated Genes in Min6 b Cells
ChIP assays illustrating Pdx1 and Brg1 genomic binding, with Brg1 enriched at
activated (Insulin, MafA R3, Pdx1 AI/II, and Pax4) Pdx1 target genes in Min6
cells. Notably, Brg1 did not bind to these control regions in Brg1+, PDX1HeLa
cells (Figure S5B) (n = 4, *p < 0.05). Error bars represent SD.PDX1 to the SWI/SNF chromatin remodeler is dynamically regu-
lated under both physiological and pathophysiological condi-
tions in islet b cells.
DISCUSSION
Modulation of target gene expression by transcription factors is
contingent upon their ability to recruit coregulator proteins, such
as those with a capacity to modify chromatin structure. Surpris-
ingly, despite the fundamental importance of transcription
factors such as Pdx1, MafB, Nkx2.2, and Nkx6.1 to islet b cell
development and function, there is a glaring deficiency in our
knowledge of how coregulators influence these and other islet-
enriched transcription factors. Thus, the goal here was to
generate an impartial and comprehensive list of coregulators
binding to Pdx1 in b cells. Our ReCLIP/MS screen returned a
substantial number of candidate coregulators with a vast
array of cellular functions, including several capable of mediating
the positive and negative transcriptional actions linked to Pdx1
(e.g., TIF1b [Iyengar et al., 2011], DNA methyltransferase 1 or
Dnmt1 [Dhawan et al., 2011], NuRD [Miccio et al., 2010], and
Swi/Snf [Flowers et al., 2009]) (Figure 2; Tables 1 and S1).
We focused our analysis on determining the significance of
the Pdx1:Swi/Snf complex in modulating b cell activity. Our
results strongly suggest that recruitment of Swi/Snf com-
plexes harboring the Brg1 ATPase is essential for Pdx1 transac-
tivation, while the Brm-Swi/Snf complexes mediate repression
(Figure S6).
Brg1 and Brm were widely produced throughout the pancre-
atic epithelium and in the surrounding mesenchyme of the
E12.5 pancreas (Figures S2A and S2B). PLA analyses revealed
Pdx1 interacts with both ATPases in nearly all cells of the multi-
potent Pdx1+ epithelium but not in the surrounding mesen-
chyme where Pdx1 is not produced (Figures S3A and S3B).
Notably, a hypoplastic pancreas phenotype was found in mice
upon the removal of floxed Brg1 early in pancreas developmentCellby Ptf1a-Cre (von Figura et al., 2014). Interestingly, all of the
mature pancreatic cell types were formed and Brg1 mutant ani-
mals were otherwise healthy, albeit final pancreas size was
reduced by 50%. Because the number of multipotent progenitor
cells limits pancreas size (Stanger et al., 2007), we propose that
reduced Brg1 decreases Pdx1+/Ptf1a+/Sox9+ progenitor num-
bers by affecting their proliferative capacity and/or health. More-
over, we further suggest that this is principally due to the actions
of Pdx1 recruitment of Swi/Snf to multipotent progenitor cell
target genes, and not Ptf1a or Sox9, as neither associated with
Swi/Snf in this cell population. It will be interesting to determine
if Brm-Swi/Snf compensates for the loss of Brg1 in this context
and how this coregulator influences Pdx1 action in adult islet b
cells.
In contrast to the extensive interactions of Pdx1:Swi/Snf
within the pancreas multipotent progenitor cell population,
complex formation became restricted to the insulin+ cells pro-
duced later in development and in islet b cells (Figures S3A and
S3B). However, as islet somatostatin hormone+ d cells and
acinar cells produce low levels of Pdx1, these results indicate
some change within Pdx1 (potentially a posttranslational modi-
fication), or simply the higher levels in b cells allows specific
recruitment of widely distributed Brg1-Swi/Snf and Brm-Swi/
Snf. Strikingly, knockdown of Brg1 and Brm in b cell lines re-
vealed that Brg1 was important for coactivation of Pdx1 target
genes (Insulin, MafA, and Glut2) and Brm corepression (Insulin,
Glut2, MafB, and Ucn3) (Figures 5A–5D). The acute conditions
of our analysis presumably enabled detection of this regulatory
pattern despite an only 50% reduction in ATPase subunit
levels, and not compensation by the unaffected coregulator
that has been observed in vivo (Bultman et al., 2000; Smith-
Roe and Bultman, 2013). Furthermore, Brg1 was found to
directly bind within Pdx1-binding control-element-containing
regions of these activated genes in ChIP assays (Figure 4; Bult-
man et al., 2000; Smith-Roe and Bultman, 2013; Willis et al.,
2012).
Next, we examined if Pdx1 binding to Brg1-Swi/Snf and Brm-
Swi/Snf was acutely regulated by changes in blood glucose
levels in vivo, specifically examining low (fasting) to high (fed)
conditions that influence Pdx1 activity in b cell lines. For
example, Insulin gene transcription is enhanced by recruitment
of the p300 coactivator, which catalyzes histone H4 hyperacety-
lation within the proximal promoter region that correlates with
gene activation (Mosley et al., 2004). Conversely, Hdac1/2
recruitment by Pdx1 at non-stimulating, low-glucose levels
inhibits transcription (Mosley and Ozcan, 2004). Similarly,
Pdx1:Brg1 activator complex formation was rapidly and signifi-
cantly increased in islet b cells by elevated blood glucose levels,
while Pdx1:Brm repressor binding was unaffected (Figures 3A–
3F). This was observed under circumstances where nuclear
Pdx1, Brg1, and Brm levels were unaffected by changing
glucose levels (Figure S7). We conclude that high-glucose con-
centrations amplified Pdx1:Brg1-Swi/Snf activator complex
formation over Pdx1:Brm-Swi/Snf, causing transcriptional acti-
vation by directly influencing nucleosome occupancy and
phasing in an ATP-dependent manner (Figures S6A and S6B).
This represents a distinct mechanism from Pdx1-recruited
p300 gene activation described above. Collectively, theseReports 10, 2032–2042, March 31, 2015 ª2015 The Authors 2037
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Figure 5. The Pdx1-Recruited Brg1- and
Brm-Containing Swi/Snf Complexes Ap-
pear to Play Opposing Regulatory Roles in
b Cells
(A–D) Treatment with (A) siBrg1 or (C) siBrm
effectively reduced protein levels over scrambled
RNAs in INS-1 cells, as demonstrated by immu-
noblot and densitometry analysis. (B) Expression
of Pdx1-activated Insulin, MafA, and Glut2 were
significantly compromised following Brg1 knock-
down, while (D) Brm knockdown had the opposite
effect, causing upregulation of Insulin, Glut2, and
non-Brg1 targets (MafB and Ucn3). The siRNA
transfections were performed in triplicate on three
separate occasions (n = 3, *p < 0.05). Error bars
represent SD.results highlight how context-dependent recruitment of physio-
logically regulated and compositionally distinct Swi/Snf com-
plexes dictate Pdx1 action and b cell function.2038 Cell Reports 10, 2032–2042, March 31, 2015 ª2015 The AuthorsPeripheral insulin resistance and islet b
cell dysfunction are the fundamental
causes of T2DM, and symptoms often
present slowly, after many years of
progressive loss of b cell function and
metabolic control. The initial response to
peripheral insulin resistance is augmenta-
tion of Islet b cell mass and function (Tal-
chai et al., 2009). However, the increasing
metabolic demand imposed on b cells is
strongly linked to their accumulation of
destructive stress molecules, such as
reactive oxygen species. The resulting
oxidative stress conditions induce delete-
rious posttranslational modifications on
proteins, affecting activity, stability, and
subcellular localization. Indeed, a selec-
tive decline in transcription factors central
to glucose sensing and insulin secretion
is observed in T2DM islet b cells (i.e.,
MAFA, MAFB, PDX1, and NKX6.1) (Guo
et al., 2013). Notably, MAFA and MAFB
are highly susceptible to oxidative stress
and their rapid loss is proposed to dictate
first-phase insulin secretion defects early
in disease progression. Persistent insults
to PDX1 and NKX6.1, however, cause a
more prolonged decline (years to de-
cades) in activity, ultimately resulting in
overt diabetes manifesting from severe
b cell dysfunction.
Although it remains unclear how these
T2DM-associated transcription factors
are rendered inoperative in vivo, we
speculate that pathophysiological con-
ditions affect coregulator binding and,
consequentially, transcription factor func-
tion. Significantly, coregulator-catalyzed
changes inepigeneticDNAmethylationandhistonemodifications
are found in T2DM islets, which influence promoter and enhancer
structures driving islet-specific gene expression (Dayeh et al.,
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Figure 6. PDX1:BRG1-SWI/SNF Activator
Levels Are Compromised in T2DM Islet b
Cells
(A–F) Representative PLA signals for PDX1 and (A)
BRG1 or (D) BRM complexes in age-, sex-, and
BMI-matched normal and T2DM human pancreas
sections; arrows indicate PLA signals and lower
magnification insets are provided to orient each
image. Scale bars, 5 mM. (B) PDX1:BRG1, but not
(E) PDX1:BRM signal levels were significantly
attenuated in T2DM b cell nuclei. (C) T2DM islets
contain 2-fold more b cells displaying no detectible
PDX1:BRG1 signal than normal controls. No sig-
nificant difference in PDX1:BRM PLA signal (E)
distribution per b cell or (F) number of b cells pre-
senting zero was observed between T2DM and
normal human islets. Paraffin sections from three
individual T2DM and normal donors were inde-
pendently analyzed and quantitated (n = 3 for
each donor of each type, *p < 0.05). Error bars
represent SD.2014; Parker et al., 2013). In addition, our PLA results illustrated
that PDX1:BRG1 activator binding was diminished in T2DM b
cells, while PDX1:BRM repressor complex formation was unaf-
fected (Figures 6A–6F). Presumably, decreased PDX1:BRG1
activator formation simply reflects the diminished levels of PDX1
protein in T2DM b cells (Guo et al., 2013), while howBRMbinding
to PDX1 is selectively retained is unclear. Posttranslational mod-
ifications of PDX1 and/or SWI/SNF subunits likely influence their
interactions, since, for example, Pdx1 transcriptional activityCell Reports 10, 2032–2042(i.e., Hdac1/2 and p300 recruitment [Mos-
ley and Ozcan, 2004; Mosley et al., 2004])
and protein destruction (Pcif1-Cul3 [Clai-
born et al., 2010]) are impacted by such
events. We propose that PDX1:BRM-
SWI/SNF activity contributes to the loss
in T2DM b cell function (Figure S6). More-
over, conditions affecting PDX1 coactiva-
tor and corepressor recruitment occur
relatively soon after exposure to insulin
resistance in the context of T2DM disease
process, and well before overt transcrip-
tion factor loss.
Overall, our results clearly demon-
strate the prominent role of Swi/Snf
in regulating Pdx1 activity in b cells.
Furthermore, we have uncovered that
Pdx1 recruitment of Brg1-Swi/Snf and
Brm-Swi/Snf is influenced by physiolog-
ical and pathophysiological settings,
which are hypothesized to have signifi-
cant implications on transcription factor
activity and b cell function. In addition,
this study illustrates how a ReCLIP/MS
strategy can be used to identify coregu-
lators of other islet-enriched transcrip-
tion factors. Such knowledge will pro-
vide valuable mechanistic insight intohow these transcription factors regulate islet cell formation,
function, and survival.
EXPERIMENTAL PROCEDURES
ReCLIP/MS
Mouse bTC-3 and human EndoC-bH1 cells were grown as defined earlier (Na-
gamatsu and Steiner, 1992; Ravassard et al., 2011). The ReCLIP procedure
was performed as described (Smith et al., 2011) with minor modifications.
Briefly, 14 15-cm culture plates of bTC-3 cells at 70% confluency (108 cells), March 31, 2015 ª2015 The Authors 2039
were exposed to freshly made DSP (stock 20 mM in DMSO) diluted to a final
concentration of 1 mM in PBS (pH 7.4) for 45 min at 37C. Nuclear extract
was prepared as previously described (Schreiber et al., 1989), except that
DTT was withheld from the extraction buffer. The nuclear extract was incu-
bated with either goat a-Pdx1 (generated by Dr. Chris Wright, Vanderbilt Uni-
versity) antibody or goat IgG (control)-bound Protein G Dynabeads for 3 hr at
4C, and then washed with RIPA buffer (100 mMNaCl, 1% Nonidet P40, 0.5%
deoxycholic acid, 0.1% SDS, 50 mM Tris/HCl [pH 8.0], and 1 mM EDTA).
Pdx1-binding partners were eluted with RIPA buffer supplemented with
200 mM DTT. Eluted proteins were analyzed via MudPIT (Multidimensional
Protein Identification Technology) as previously described (Martinez et al.,
2012) in the Vanderbilt University Medical Center Proteomics Core. MS anal-
ysis was performed on at least three independent ReCLIP preparations, with
each showing similar enrichment of specific peptides.
coIPs and Immunoblotting
bTC-3 nuclear extracts were incubated with either goat a-Pdx1 (generated by
Dr. Chris Wright, Vanderbilt University), rabbit a-Brg1 (Santa Cruz Biotech-
nology, H88-X), rabbit a-Tif1b (Abcam, ab10483), rabbit a-Mi2b (Abcam,
ab72418) antibody, or species-matched IgG (control)-bound Protein G Dyna-
beads for 3 hr at 4C, as described previously (Hunter et al., 2013). The immu-
noprecipitates were fractionated by SDS-PAGE (NuPAGE 10% Bis-Tris gels),
transferred onto polyvinylidene fluoride (PVDF) membrane, and probed with
the following antibodies: goat a-Pdx1 (1:10,000); rabbit a-Brg1 (Santa Cruz,
H88-X, 1:5,000); rabbit a-Brm (Cell Signaling Technology, 6889S, 1:2,000);
rabbit a-Tif1b (Abcam, ab10483, 1:2,000); rabbit a-RBBP4 (Bethyl Labora-
tories, A301-206A, 1:2,000); rabbit a-Mi2b (Abcam, ab72418, 1:2,000); rabbit
a-Beta-Actin (Cell Signaling Technology, 4967S, 1:2,000); HRP-conjugated
a-rabbit IgG (Promega, 1:2,000), and HRP-conjugated a-goat IgG (Santa
Cruz, 1:2,000). The experiments were performed at least three times and quan-
titated using NIH ImageJ software.
Sucrose Gradient Ultracentrifugation and EMSA
Sucrose gradients were performed as previously described (Guo et al., 2010).
Briefly, bTC-3 nuclear extract (1.5–2.5 mg) were separated over a 10%–35%
sucrose gradient (4.5 ml total volume). Fractions (300 ml each, excluding the
first 500 ml) were analyzed by immunoblotting, mouseMafA Region 3 element
binding in EMSAs (Guo et al., 2010), and by immunoprecipitation.
Immunofluorescence
Tissue fixation, embedding, and immunofluorescence labeling were per-
formed as previously described (Matsuoka et al., 2003). The primary anti-
bodies used were goat a-Pdx1 (1:15,000), rabbit a-Brg1 (1:300), rabbit
a-Brm (Abcam, ab72418, 1:300), and guinea pig a-insulin (Dako, A0546,
1:500). The secondary Cy2-, Cy3-, or Cy5-conjugated donkey a-rabbit,
a-guinea pig, and a-goat IgGs were obtained from Jackson ImmunoResearch
Laboratories. Nuclear counterstaining was performed using DAPI (Invitrogen).
Immunofluorescence images were acquired by fluorescence microscopy us-
ing a Zeiss Axioimager M2 and processed by NIH ImageJ software.
PLA
Paraffin-embedded human pancreas, mouse embryonic, and adult pancreas
samples were analyzed by procedures described by the PLA kit manufacturer
(Olink Bioscience), with minor modifications. Slides were de-waxed/rehy-
drated as previously described (Matsuoka et al., 2003). Heat antigen retrieval
in 13TEG (25 mM Tris HCl (pH 8), 10 mM EDTA, and 50 mM glucose) was fol-
lowed by three 10-min 13PBSwashes. A 1%BSA/PBS blocking solution sup-
plementedwith 5%normal donkey serumwas applied for 2 hr at room temper-
ature. The following primary antibodies were incubated in a humidity chamber
overnight at 4C: goat a-Pdx1 (1:15,000), rabbit a-Brg1 (1:300), rabbit a-Brm
(Abcam, ab72418, 1:300), mouse a-glucagon (Sigma-Aldrich, g2654-0.5ml,
1:4,000), and guinea pig a-insulin (1:500). Immunofluorescence images were
acquired on a Zeiss Axioimager M2 and processed for counting analysis using
NIH ImageJ software. The discrete fluorescent nuclear PLA spots were
counted from at least three pancreas sections per experimental animal or hu-
man donor. The Gift of Hope Organ Procurement Organization in Chicago
generously provided human pancreata, which were obtained from three2040 Cell Reports 10, 2032–2042, March 31, 2015 ª2015 The Authornormal and three T2DM de-identified cadaver donors: normal, two male and
one female (59.3 ± 8.5 years [range: 51 to 68], BMI 22.6 ± 2.4 [range: 21.1 to
25.4]); T2DM, two male and one female (57.0 ± 5.3 years [range: 51 to 61],
BMI 25.9 ± 7.1 [range: 21.2 to 34]).
ChIP Assays
Mouse Min6 b cells (43 106 cells) were 1% formaldehyde cross-linked, and
the sonicated protein-DNA complexes isolated under conditions described
previously (Gerrish et al., 2001). The fragmented chromatin was incubated
with a-Pdx1, a-Brg1, a-Brm, or species-matched IgG (Bethyl Laboratories),
and the complexes isolated with BSA- or herring sperm single-stranded
DNA (ssDNA) (Abcam, ab46666)-blocked protein-A Dynabeads (Invitrogen).
Quantitative real-time PCR was performed using SYBR Green master mix in
a Roche LightCycler 480II. The PCR primers were as follows: MafB 742 to
938 (site1), forward 50-TTAGCGCAGACAGAGCTACCGAAA-30, reverse 50-
ATACTCTTTACACTCCCACCCTCG-30; Glucagon +70 to 148 (contains G1
element), forward 50-CGTAAAAAGCAGATGAGCAAAGTG-30, reverse 50-GAA
CAGGTGTAGACAGAGGGAGTCC-30; Pax4 1,841 to 1,966 (contains
b cell-specific enhancer), forward 50-CCAACGATCCAGGCTCTACATC-30,
reverse 50-CGGGTTTGGGGCTAATTGTCC-30; Pdx1 2,471 to 2,598 (con-
tains Area I), forward 50-TGGCTCGGGAAGGCTCTTG-30, reverse 50-CCAT
CAGGTGGCTAAATCCATTATG-30; IAPP 97 to 190, forward 50-TCACCCA
CACAAAGGCACTCAG-30, reverse 50-GGTTTCATTGGCAGATGGAGC-30;
MafA R3, forward 50-CTGGAAGATCACCGCACA-30, reverse 50-ATTTACCA
AGCCCCAAACG-30; Insulin (proximal promoter), forward 50-GCCATCTGCT
GACCTACCC-30, reverse 50-CCCCTGGACTTTGCTGTTT-30; and Albumin
3,164 to 3,342 (distal TAAT-containing region), forward 50-TGGGA
AAACTGGGAAAACCATC-30, reverse 50-CACTCTCACACATACACTCCTGC
TG-30. Experiments were performed with at least three independently isolated
chromatin preparations.
siRNA Knockdown and RNA Analysis
Rat INS-1 cells (7.53 105 per well) were seeded into six-well plates and target-
ing Brg1, Brm, or scrambled control siRNAs (Dharmacon) introduced using
Lipofectamine 2000 (Invitrogen). RNA and immunoblot protein studies were
performed 72 hr following treatment. Cellular RNA was isolated using the
QIAGEN RNeasy Mini Kit. cDNA was prepared from RNA using the iScript
cDNA synthesis kit (Bio-Rad), and quantitative real-time PCR was performed
using SYBR Green master mix and a Roche LightCycler 480II. The experi-
mental data were normalized to glyceraldehyde-3-phosphate dehydrogenase
(Gapdh) mRNA levels, and relative changes were calculated by the compara-
tive DCt method (Chakrabarti et al., 2002).
Glucose Treatment Conditions
C57BL/6 mice (Charles River Laboratories) were fasted from 18:00 to 10:00 hr,
and then blood glucose measurements were taken from the tail tip using an
Aviva glucometer (Accu Chek). Glucose was administered to the high group
by intraperitoneal injection of a 20% glucose solution to achieve a final dose
of 2 g/kg body weight. Glucose measurements were taken at 0, 15, and
30 min post-injection. Pancreata were harvested from each group and tissue
embedded as previously described (Matsuoka et al., 2003).
Statistics
Data are expressed as the means ± SD. p values were calculated with a Stu-
dent’s two-tailed test. Results were considered significant at p < 0.05.
Study Approval
The institutional review board at the University of Chicago and Vanderbilt Uni-
versity approved the use of human tissues in these studies. The Vanderbilt Uni-
versity Institutional Animal Care and Use Committee approved all studies
involving animals.
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